



CMP	69	Rating	BUY	Result (Rs.bn)	Q3FY18	Q3FY17	Q2FY18	Y/Y(%)	Q/Q(%)
Target	94	Upside	35%	Revenue	11.4	11.2	11.5	1.46	-1.53
				EBITDA	2.0	2.3	1.7	-11.2	15.4
				EBITDA(%)	17.6	20.1	15.0	-250bps	258bps
				PAT	0.7	0.8	0.5	-7.0	43.5
				PAT(%)	6.4	7.0	4.4	-59bps	201bps
				EPS	1.4	1.5	1.0	-7.0	43.5

**Marginal Revenue growth** – For the qtr, Trident reported a revenue growth of 1.46% YoY to Rs 11.37bn. The textile segment (~80% of sales) grew by a mere 0.2% YoY to Rs 9.13bn, while the paper segment posted a tepid growth of 0.7% YoY to Rs 2.24bn.

**OPM Falter**- For the Qtr, Trident reported a EBITDA of Rs 2.0bn a decline of 11.2% YoY, while OPM contracted by 250bps YoY to 17.6%. The decline was on back of 488bps YoY increase in RMAAT cost, however a 335bps YoY decline in employee expenses arrested overall decline.

EBIT for the textile stood at 8.0% a decline on 131bps YoY, while EBIT margins for the paper segment reported a growth of 258bps YoY to 28.8%.

**Higher tax rate impede PAT**- Trident reported a PAT decline of 7% YoY to Rs 0.73bn. The decline was on back of poor operating performance and higher tax rate (30.5% vis-à-vis 23.10%). Increase in other income (+1.96x YoY) negated overall decline.

STOCK DETAILS	
BSE Code	521064
NSE Code	TRIDENT
Market Cap (Rs.mn)	35197
Sector/ Index	Textiles
Year End	March
52 w.High/Low	109/49
Avg monthly Turnover (Rs.Mn)	138.5mn
Shares in Issue (mn)	569.37
BSE Sensex	34196
NSE Nifty	10498

**About the company:** Trident Limited is the flagship company of the Punjab-based conglomerate Trident Group, having a turnover of ~Rs 47bn. Trident manufactures textile products (terry towels, bed linen, cotton yarns, blended yarns among others), paper, chemical and energy. After commissioning its Budni unit, Trident became the largest terry towel manufacturer globally. To widen its product basket, the Company has embarked on becoming one of the major bed linen manufacturers in the country by installing 500 state-of-the-art looms at its Budni plant.

CONSOLIDATED FINANCIALS				
Rs in bn	FY16	FY17E	FY19E	FY20E
Total Revenue	46.9	46.7	51.0	56.2
EBITDA	8.9	9.4	10.5	11.9
EBITDA(%)	18.9%	20.0%	20.6%	21.2%
PAT	3.37	3.80	4.62	5.90
EPS (Rs.)	6.6	7.5	9.1	11.6
P/E (x)	10.5x	9.3x	7.6x	6.0x

Source: Company, Bloomberg Consensus

#### Key Takeaways:

**Headwinds Persist**- Due to uneven procurement cycle & destocking by some of large customers in US, the Industry saw pressure in volumes in Q2 of FY18 which also continued in Q3 FY18. Further, stronger rupee and higher raw material prices due to unavailability of quality cotton continue to remain key headwinds for the Textile Industry. The company expects some kind of recovery and restocking by US customers by Q4FY18 and Q1FY19E Onwards.

**Capacity Utilization**- Bed Linen registered 44% volume growth in 9M FY18 and Bath Linen registered 12% volume de-growth in 9M FY18 compared to the same period last year. Bath Linen 9M average Capacity Utilization stood at 45% and Bed Linen capacity utilization over 9M period stood at 42%. The management is confident of meeting the annual guidance of 55% capacity utilization for bath linen and 40-50% for bed linen.

**Cotton Scenario**- Arrival of Cotton this season was decent as anticipated and price was down nearly 15% as compared to last season. But due to quality issues the cotton prices started going up during December and currently the price is almost up 10% from bottom. Cotton spreads have now stabilized, and clarity has emerged on the duty drawback and RoSL.

**Paper segment**- Realizations were flat for paper division but low for chemicals; margins in paper & chemicals division suffered slightly due to rise in raw material and soft realizations. Share of copier paper in the overall paper volume at the end of 9month ending Dec.'17 was 48% as compared to 52% for FY17.

**Valuation and View:** Trident's margin profile during the qtr was impacted due to erratic vendor procurement cycle in the US. Further higher rupee and unavailability of quality cotton further hampered the overall sentiments. However, the management expects to see recovery by Q1FY19.

On back of these current scenario we have downgraded our sales estimate for FY18E and FY19E by 4% and 3% respectively. Further given the erratic vendor cycle in US markets have also brought the margins under pressure and hence we have downgraded our overall margins by 70bps and 100bps for FY18E and FY19E respectively. Hence, overall earnings have been downgraded by 8% and 10% for FY18E and FY19E. We have also introduced FY20e earning estimates as well.

We now expect the company to post a revenue CAGR growth of 6% over FY17-20. While margins are likely to improve by 230bps YoY to 21.2% over the same period. Margins are likely to improve on back of higher utilization levels in home textile segment and higher share of copier paper by FY20. We expect PAT to grow at CAGR of 21% over the same period as financial leverage plays out then.

At CMP of Rs 69.20 the stocks trades at 7.6x FY19E and 6.0x FY20E on expected earnings of Rs 9.1 (Rs 10.3) and Rs 11.6 respectively. We believe Trident is well placed to reap the benefits of the expected recovery in US market given the company's product profile. The textile sector has witnessed a erosion in valuations band on back of prolonged skewness in demand in the US markets, this has led to companies trading at an average of 10x 1yr forward against 13x in H1FY18. Hence, we assign a PE multiple of 9x as on Sept 19 earnings of Rs 10.40, post which we arrive at a target of Rs 94 an upside of 35% from current levels. We assign a BUY rating on the stock.

SUMMARY INCOME STATEMENT							
(in mn)	FY14	FY15	FY16	FY17	FY18E	FY19E	FY20E
Total Income	38,690	37,553	36,657	46,944	46,749	50,994	56,243
Cost Of Revenues (incl Stock Adj)	20,521	19,309	17,286	22,916	24,310	26,517	26,996
<b>Gross Profit</b>	<b>18,169</b>	<b>18,245</b>	<b>19,370</b>	<b>24,028</b>	<b>22,440</b>	<b>24,477</b>	<b>29,246</b>
Employee Cost	2,870	3,872	4,295	5,794	5,142	5,864	6,468
<b>Other Operating Expenses</b>	<b>8,023</b>	<b>7,766</b>	<b>7,778</b>	<b>9,351</b>	<b>7,938</b>	<b>8,121</b>	<b>10,840</b>
EBITDA	7,276	6,608	7,297	8,882	9,359	10,492	11,939
Other Income	163	345	334	1,035	1,262	1,122	1,237
<b>Net Interest Exp.</b>	<b>2,103</b>	<b>2,060</b>	<b>1,452</b>	<b>1,410</b>	<b>1,210</b>	<b>963</b>	<b>715</b>
Depreciation	2,684	3,213	3,366	4,125	4,137	4,239	4,268
Exceptional Items	0	0	0	0	0	0	0
<b>PBT</b>	<b>2,652</b>	<b>1,680</b>	<b>2,813</b>	<b>4,382</b>	<b>5,274</b>	<b>6,413</b>	<b>8,193</b>
Tax	681	501	392	1,016	1,477	1,796	2,294
Profit After Tax	1,971	1,179	2,421	3,366	3,797	4,617	5,899
<b>Net Profit</b>	<b>1,971</b>	<b>1,179</b>	<b>2,421</b>	<b>3,366</b>	<b>3,797</b>	<b>4,617</b>	<b>5,899</b>
EPS	3.8	2.3	4.8	6.6	7.5	9.1	11.6

SUMMARY BALANCE SHEET							
(in mn)	FY14	FY15	FY16	FY17	FY18E	FY19E	FY20E
<b>Assets</b>							
Net Block	17,955.9	28,639.0	46,930.4	43,448.0	40,908.2	37,169.3	33,401.3
Capital WIP	276.9	1,993.0	571.3	1,097.6	0.0	0.0	0.0
Intangible Assets under development	85.9	225.9	43.9	134.0	134.0	134.0	134.0
Non-current Investment	997.0	112.0	721.6	1,005.0	1,005.0	4,917.1	8,828.3
Long term loans and advances	1,514.4	1,727.9	1,291.6	1,085.7	1,085.7	1,085.7	1,085.7
<b>Current Assets</b>							
Current Investment	155.0	196.5	1.1	48.9	48.9	483.6	483.6
Inventories	6,428.5	7,507.8	9,065.5	7,747.2	7,044.4	6,985.5	7,550.4
Trade receivables	2,641.4	2,033.3	2,512.7	3,750.9	3,586.2	3,772.2	4,006.3
Cash and cash equivalents	250.1	170.1	819.4	1,326.3	5,887.8	5,502.2	6,409.7
Short-term loans and advances	1,487.8	2,442.5	306.2	316.5	256.2	419.1	308.2
Other Current Assets	22.0	22.0	3,029.2	1,904.9	1,904.9	1,904.9	1,904.9
<b>Total Current Assets</b>	<b>10,829.8</b>	<b>12,175.7</b>	<b>15,733.0</b>	<b>15,045.8</b>	<b>18,679.5</b>	<b>18,583.9</b>	<b>20,179.4</b>
<b>Current Liabilities &amp; Provisions</b>							
Short-term borrowings	8,038.8	8,156.0	9,732.8	8,038.5	8,038.5	7,538.5	7,038.5
Trade payables	1,852.5	2,190.6	2,237.1	2,302.2	2,177.4	2,375.1	2,311.3
Other current liabilities	3,665.8	4,517.1	4,344.5	3,814.0	3,586.2	3,772.2	4,006.3
Short-term provisions	193.3	44.6	63.2	76.3	128.1	139.7	308.2
Total Current Liabilities	5,711.6	6,752.3	6,644.8	6,192.5	5,891.7	6,286.9	6,625.8
<b>Net Current Assets</b>	<b>5,118.2</b>	<b>5,423.4</b>	<b>9,088.1</b>	<b>8,853.3</b>	<b>12,787.8</b>	<b>12,297.0</b>	<b>13,553.6</b>
<b>Total Assets</b>	<b>26,103.3</b>	<b>38,317.7</b>	<b>58,648.0</b>	<b>55,672.5</b>	<b>55,969.6</b>	<b>56,086.7</b>	<b>57,486.5</b>
<b>Liabilities</b>							
Share Capital	3,110.9	5,086.4	5,093.7	5,095.8	5,095.8	5,095.8	5,095.8
Reserves and Surplus	5,737.4	9,467.1	19,267.3	22,472.6	26,269.7	30,886.7	36,785.6
<b>Total Shareholders Fudn</b>	<b>8,848.3</b>	<b>14,553.5</b>	<b>24,361.0</b>	<b>27,568.4</b>	<b>31,365.5</b>	<b>35,982.5</b>	<b>41,881.4</b>
Money Received against warrants	430.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total Debt</b>	<b>15,697.4</b>	<b>22,117.0</b>	<b>31,097.9</b>	<b>25,501.4</b>	<b>22,001.4</b>	<b>17,501.4</b>	<b>13,001.4</b>
Long Term Provisions	45.3	405.1	84.6	140.4	140.4	140.4	140.4
Other Long Term Liabilities	0.0	0.0	1,522.9	807.3	807.3	807.3	807.3
Net Deferred Tax Liability	1,082.3	1,242.1	1,581.7	1,655.1	1,655.1	1,655.1	1,655.1
<b>Total Liabilities</b>	<b>26,103.3</b>	<b>38,317.7</b>	<b>58,648.0</b>	<b>55,672.5</b>	<b>55,969.6</b>	<b>56,086.7</b>	<b>57,486.5</b>

SUMMARY CASH FLOW STATEMENT							
(in mn)	FY14	FY15	FY16	FY17	FY18E	FY19E	FY20E
PBT	2,652	1,680	2,766	4,382	5,274	6,413	8,193
Depreciation & Amort., Total	2,684	3,213	3,376	4,125	4,137	4,239	4,268
After other adjustments	2,282	1,871	1,170	1,410	1,210	963	715
(Inc) / Dec in Working Capital	23	(977)	(1,424)	1,003	627	105	(349)
Taxes	(584)	(347)	(600)	(927)	(1,477)	(1,796)	(2,294)
Others							
<b>Cash from Ops.</b>	<b>7,056</b>	<b>5,441</b>	<b>5,288</b>	<b>9,994</b>	<b>9,772</b>	<b>9,924</b>	<b>10,533</b>
Capital Expenditure & investments	(1,731)	(1,429)	(12,001)	(1,869)	(500)	(4,847)	(4,411)
<b>Cash from Investing</b>	<b>(1,731)</b>	<b>(1,429)</b>	<b>(12,001)</b>	<b>(1,869)</b>	<b>(500)</b>	<b>(4,847)</b>	<b>(4,411)</b>
Issue of Share capital	3	187	611	2	-	-	-
Net Borrowings	(4,062)	(1,966)	7,809	(5,596)	(3,500)	(4,500)	(4,500)
Others	(1,676)	(2,056)	(1,367)	(1,410)	(1,210)	(963)	(715)
Issuance of Dividend	(5)	(486)	(360)	-	-	-	-
<b>Cash from Financing</b>	<b>(5,740)</b>	<b>(4,321)</b>	<b>6,694</b>	<b>(7,005)</b>	<b>(4,710)</b>	<b>(5,463)</b>	<b>(5,215)</b>
Extraordinary receipts/payment	-	-	-	18	-	-	-
<b>Net Change in Cash</b>	<b>(415)</b>	<b>(309)</b>	<b>(20)</b>	<b>1,139</b>	<b>4,561</b>	<b>(386)</b>	<b>906</b>
BF Cash	91	89	69	49	1,188	5,749	5,364
Cash from Merger	-	290	-	-	-	-	-
END Cash	<b>(323)</b>	<b>69</b>	<b>49</b>	<b>1,188</b>	<b>5,749</b>	<b>5,364</b>	<b>6,270</b>

SUMMARY RATIOS							
	FY14	FY15	FY16	FY17	FY18E	FY19E	FY20E
<b><u>Profitability</u></b>							
Return on Assets	6.1%	2.6%	3.7%	5.5%	6.1%	7.4%	9.2%
Return on Capital	19.0%	10.2%	7.7%	10.9%	12.1%	13.8%	16.2%
Return on Equity	20.9%	8.1%	9.9%	12.2%	12.1%	12.8%	14.1%
<b><u>Margin Analysis</u></b>							
Gross Margin	47.0%	48.6%	52.8%	51.2%	48.0%	48.0%	52.0%
EBITDA Margin	18.8%	17.6%	19.9%	18.9%	20.0%	20.6%	21.2%
Net Income Margin	5.1%	3.1%	6.6%	7.2%	8.1%	9.1%	10.5%
<b><u>Short-Term Liquidity</u></b>							
Current Ratio	0.8x	0.8x	1.0x	1.1x	1.3x	1.4x	1.5x
Quick Ratio	0.3x	0.3x	0.4x	0.5x	0.8x	0.9x	1.0x
Avg. Days Sales Outstanding	25	20	25	29	28	27	26
Avg. Days Inventory Outstanding	61	73	90	60	55	50	49
Avg. Days Payables	17	21	22	18	17	17	15
<b><u>Long-Term Solvency</u></b>							
Total Debt / Equity	1.7x	1.5x	1.3x	0.9x	0.7x	0.5x	0.3x
EBITDA / Interest Expense	2.3x	1.8x	2.9x	4.1x	5.4x	7.7x	12.5x
<b><u>Valuation Ratios</u></b>							
EV/EBITDA	5.1x	8.6x	9.0x	6.7x	5.5x	4.5x	3.5x
PER	18.1x	29.9x	14.5x	10.5x	9.3x	7.6x	6.0x
P/B	2.3x	2.4x	1.4x	1.3x	1.1x	1.0x	0.8x

## INDSEC Rating Distribution

**BUY** : Expected total return of over 25% within the next 12 months.

**ACCUMULATE** : Expected total return between 10 to 25% within the next 12 months.

**REDUCE** : Expected total return below 10% within the next 12 months.

**SELL** : Expected total return is below the market return within the next 12 months.

**NEUTRAL**: No investment opinion on the stock under review.

## DISCLOSURE

### BUSINESS ACTIVITIES:

Indsec Securities and Finance Limited (ISFL) is a corporate member of BSE in Equity, WDM segment and of NSEIL in Equity, WDM, Futures & Options and Currency Derivative segments. ISFL is also a Depository Participant of the National Securities Depository Limited (NSDL) and a SEBI registered Portfolio Manager. ISFL has also secured membership of the MCX Stock Exchange in Currency Derivative Segment. With this setup ISFL is in a position to offer all types of services in the securities industry.

Since inception company's focus has been on research. In view of its research capabilities ISFL focused mainly on institutional business and is today empanelled with most of the local financial institutions, insurance companies, banks and mutual funds. ISFL has grown from being a medium size broking outfit to become one of the largest capitalized Indian broking company offering the complete range of broking services.

ISFL was incorporated on 28th July 1993 and doesn't have any associates/ subsidiaries. ISFL is a registered Portfolio Manager under SEBI (Portfolio Managers) Regulations, 1993 vide registration No. INP000001892.

### DISCIPLINARY HISTORY:

- No material penalties / directions have been issued by the SEBI under the securities laws, SEBI Act or Rules or Regulations made there under
- No penalties have been imposed for any economic offence by any authority.
- No material deficiencies in the systems and operations of the Company have been observed by any regulatory agency.
- There are no pending material litigations or legal proceedings, findings of inspections or investigations for which action has been taken or initiated by any regulatory authority against the Company or its Directors, principal officers or employees or any person directly or indirectly connected with the Company.

### DECLARATION:

- ISFL does not have any financial interest in the subject company (ies);
- ISFL does not have actual or beneficial ownership of 1 % or more in the subject company (ies);
- ISFL does not have any material conflict of interest in the subject company(ies) at the time of publication of this document;
- ISFL has not received any compensation from the subject company (ies) in the past twelve months;
- ISFL has not managed or co-managed public offering of securities for the subject company (ies) in the past twelve months;
- ISFL has not received any compensation for investment banking or merchant banking or brokerage services or any other service from the subject company (ies) in the past twelve months;
- ISFL has not received any compensation or other benefits from the subject company (ies) or third party in connection with this document;
- None of the research analysts have served as an officer, director or employee of the subject company (ies);
- ISFL has not been engaged in the market making activity for the subject company (ies);

### GENERAL TERMS AND CONDITION/ DISCLAIMERS:

This document has been issued by ISFL and is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of security.

This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. However, we do not guarantee its accuracy and the information may be incomplete and condensed. Note however that, we have taken meticulous care to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any other employee of our company is in any way responsible for its contents. The Company's research department has received assistance from the subject company (ies) referred to in this document including, but not limited to, discussions with management of the subject company (ies). All opinions, projections and estimates constitute the judgment of the author as of the date of this document and these, including any other information contained in this document, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. While we would endeavor to update the information herein on reasonable basis, we are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent us from doing so.

Securities recommended in this document are subject to investment risks, including the possible loss of the principal amount invested. Any decision to purchase/sale securities mentioned in this document must take into account existing public information on such security or any registered prospectus. The appropriateness of a particular investment, decision or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this document may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved).

This document is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject the company to any registration or licensing requirement within such jurisdiction. Further, this document is not directed or intended for distribution to the US taxpayers covered under US Foreign Account Tax Compliance Act (FATCA) provisions. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction

This is just a suggestion and the company will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of the company. No matter contained in this document may be reproduced or copied without the consent of the company. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in this document is intended solely for the recipient and may not be further distributed by the recipient. The Company accepts no liability whatsoever for the actions of third parties.

The research analyst(s) of this document certifies that all of the views expressed in this document accurately reflect their personal views about those issuer(s) or securities. **Analyst's holding in the stocks mentioned in the Report:-NIL**

**CONTACT DETAILS**

Management	Designation	Email ID	Direct No. (+91-22)
Nandkishore Gupta	Managing Director	<a href="mailto:ngupta@indsec.com">ngupta@indsec.com</a>	6114 6101/02
Research Team	Designation [Sectors Covered]	Email ID	Direct No. (+91-22)
Milan Wadkar	Head - Institutional Equities	<a href="mailto:milanw@indsec.co.in">milanw@indsec.co.in</a>	6114 6105
Rahul Dani	Research Analyst (Auto, Media, Textiles & Midcap)	<a href="mailto:rahuld@indsec.co.in">rahuld@indsec.co.in</a>	6114 6116
Jimeet Shah	Research Analyst (Cap Good, Infra& Midcap)	<a href="mailto:jimeets@indsec.co.in">jimeets@indsec.co.in</a>	6114 6109
Ayush Jain	Research Associate (Banking, Pharma & Midcap)	<a href="mailto:ayushjain@indsec.co.in">ayushjain@indsec.co.in</a>	6114 6140
Kimberly Paes	Research Associate (FMCG, Cement & Midcap)	<a href="mailto:kimberlyp@indsec.co.in">kimberlyp@indsec.co.in</a>	6114 6111
Deepesh Panchawala	Technical Analyst	<a href="mailto:deepeshp@indsec.co.in">deepeshp@indsec.co.in</a>	6114 6138
Institutional Sales Team	Designation	Email ID	Direct No. (+91-22)
Parag Shah	Sales Trader	<a href="mailto:parags@indsec.co.in">parags@indsec.co.in</a>	6114 6133
Aashish Parekh	Asst. Sales Trader	<a href="mailto:aashishp@indsec.co.in">aashishp@indsec.co.in</a>	6114 6134

For additional information please contact: [research@indsec.co.in](mailto:research@indsec.co.in), or visit us at [www.indsec.co.in](http://www.indsec.co.in)

Indsec Securities & Finance Ltd, 301/302, "215 Atrium", "A" Wing, Andheri-Kurla Road, Chakala, Andheri (East), Mumbai - 400 093  
Telephone: +91 22 6114 6114 / 6114 6100, Fax: +91 22 6114 6180 / 86